Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

BCL2-inhibitor venetoclax is used to treat relapsed/refractory chronic lymphocytic leukemia (CLL). Here, the authors show the clonal dynamics towards venetoclax resistance by performing whole-exome sequencing of 8 CLL patients undergoing venetoclax treatment.

Bibliographic Details
Main Authors: Carmen D. Herling, Nima Abedpour, Jonathan Weiss, Anna Schmitt, Ron Daniel Jachimowicz, Olaf Merkel, Maria Cartolano, Sebastian Oberbeck, Petra Mayer, Valeska Berg, Daniel Thomalla, Nadine Kutsch, Marius Stiefelhagen, Paula Cramer, Clemens-Martin Wendtner, Thorsten Persigehl, Andreas Saleh, Janine Altmüller, Peter Nürnberg, Christian Pallasch, Viktor Achter, Ulrich Lang, Barbara Eichhorst, Roberta Castiglione, Stephan C. Schäfer, Reinhard Büttner, Karl-Anton Kreuzer, Hans Christian Reinhardt, Michael Hallek, Lukas P. Frenzel, Martin Peifer
Format: Article
Language:English
Published: Nature Publishing Group 2018-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-03170-7

Internet

https://doi.org/10.1038/s41467-018-03170-7

Similar Items